In fact, the combination of the CSF-1R inhibitor cabiralizumab, the PD-1 inhibitor nivolumab, and gemcitabine failed to improve the progression-free survival of advanced pancreatic cancer patients compared to gemcitabine alone. The gene discussed is CSF1R; the disease is pancreatic neoplasm.